You have 9 free searches left this month | for more free features.

City

Barcelona (1)

Houston (1)

Madrid (1)

Marseille (1)

Pittsburgh (1)

San Antonio (1)

Toronto (1)

Condition

Breast Cancer (1)

Metastatic or Locally Advanced Unresectable Solid Tumors (1)

Non-Small Cell Lung Cancer (1)

Overall Status

Not yet recruiting (2)

Recruiting (1)

Sign in for free

Phase

phase 1/phase 2 (2)

phase 1 (1)

Sponsor

EMD Serono Research & Development Institute, Inc. (2)

Institut Paoli-Calmettes (1)

Collaborator

Merck KGaA, Darmstadt, Germany (2)

Merck Sharp & Dohme LLC (1)

National Cancer Institute, France (1)

Intervention

m1774 (3)

cemiplimab (1)

drug a (dna damage response inhibitor) (1)

drug b (immune checkpoint inhibitor) (1)

fulvestrant injection (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

m1774

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

Not yet recruiting

Breast Cancer

M1774
Fulvestrant injection

Marseille, France

Institut Paoli Calmettes

Aug 9, 2023

NSCLC Trial in Pittsburgh (M1774, Cemiplimab)

Not yet recruiting

Non-Small Cell Lung Cancer

M1774
Cemiplimab

Pittsburgh, Pennsylvania

UPMC Cancer Center

May 22, 2023

Metastatic or Locally Advanced Unresectable Solid Tumors Trial in Canada, Spain, United States (M1774, Drug A (DNA Damage

Recruiting

Metastatic or Locally Advanced Unresectable Solid Tumors

M1774
+2 more

Houston, Texas
+4 more

Jul 7, 2022